Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA

SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections, announced today that the results from ESTABLISH 1, a Phase 3 study of tedizolid phosphate (TR-701) versus linezolid (Zyvox®) completed in 2011, have been published in
Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news